Beam Therapeutics Inc (NASDAQ:BEAM) — Market Cap & Net Worth
Market Cap & Net Worth: Beam Therapeutics Inc (BEAM)
Beam Therapeutics Inc (NASDAQ:BEAM) has a market capitalization of $2.63 Billion ($2.63 Billion) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5225 globally and #1739 in its home market, demonstrating a -1.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beam Therapeutics Inc's stock price $25.52 by its total outstanding shares 102879214 (102.88 Million). See Beam Therapeutics Inc (BEAM) capital reinvestment to understand how much of operating cash flow is reinvested back into capital assets.
Beam Therapeutics Inc Market Cap History: 2020 to 2026
Beam Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows growth from $8.40 Billion to $2.63 Billion (4.87% CAGR).
Index Memberships
Beam Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.11% | #130 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.01% | #591 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.15% | #82 of 263 |
Weight: Beam Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Beam Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beam Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
20.41x
Beam Therapeutics Inc's market cap is 20.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $8.40 Billion | $24.00K | -$194.59 Million | 349960.79x | N/A |
| 2021 | $8.20 Billion | $51.84 Million | -$370.64 Million | 158.14x | N/A |
| 2022 | $4.02 Billion | $60.92 Million | -$289.09 Million | 66.05x | N/A |
| 2023 | $2.80 Billion | $377.71 Million | -$132.53 Million | 7.41x | N/A |
| 2024 | $2.55 Billion | $63.52 Million | -$376.74 Million | 40.17x | N/A |
| 2025 | $2.85 Billion | $139.74 Million | -$79.99 Million | 20.41x | N/A |
Competitor Companies of BEAM by Market Capitalization
Companies near Beam Therapeutics Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Beam Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Beam Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Beam Therapeutics Inc's market cap moved from $8.40 Billion to $ 2.63 Billion, with a yearly change of 4.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.63 Billion | -7.94% |
| 2025 | $2.85 Billion | +11.77% |
| 2024 | $2.55 Billion | -8.89% |
| 2023 | $2.80 Billion | -30.40% |
| 2022 | $4.02 Billion | -50.92% |
| 2021 | $8.20 Billion | -2.39% |
| 2020 | $8.40 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Beam Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.63 Billion USD |
| MoneyControl | $2.63 Billion USD |
| MarketWatch | $2.63 Billion USD |
| marketcap.company | $2.63 Billion USD |
| Reuters | $2.63 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targ… Read more